Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > Phizer and Moderna expected to earn 32 billion from vaccines
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(443)
•••
Comment by saintpeteron Dec 13, 2020 2:48pm
77 Views
Post# 32096092

RE:RE:RE:RE:RE:Phizer and Moderna expected to earn 32 billion from vaccines

RE:RE:RE:RE:RE:Phizer and Moderna expected to earn 32 billion from vaccinesBlig have you every invested in a pharma deal like this before, I know this is my first kick at the cat 
we have no idea what goes on in the back ground and I'm sure most of us would like to hear new's 
more often like the military just didn't walk up to vxl and say hey you guy's we want to test your stuff on mice this must have involved alot of talking back and forth so I'm just waiting for word on it I believe that we have something quite promising here and will be rewarded with a bye out in the future thats why insiders bye in deals like this remember your blood pressure lol stay calm and safe

Cheer's 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities